Kelly Collins

Kelly Collins

Auto-generated profile, based on publicly available information

Kelly Collins

Division of Transplant and Hepatobiliary Surgery, Henry Ford Health System, Detroit, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Gastroenterology
Verified
Journal Article
Open access
SNShunji Nagai
Shunji Nagai
LCLucy C. Chau
Lucy C. Chau
RSRandolph E. Schilke
Randolph E. Schilke
MSMohamed Safwan
Mohamed Safwan
MRMichael Rizzari
Michael Rizzari
DMDilip Moonka
Dilip Moonka
The Model for End-stage Liver Disease and Sodium (MELD-Na) score was introduced for liver allocation in January 2016. We evaluated the effects of liver allocation, based on MELD-Na score, on waitlist and post-transplantation outcomes. We examined 2 patient groups from the United Network for Organ Sharing registry; the MELD-period group was composed of patients who were registered as transplant candidates from June 18, 2013 through January 10, 2016 (n = 18,850) and the MELD-Na period group was composed of patients who were registered from January 11, 2016 through September 30, 2017 (n = 14,512). We compared waitlist and post-transplantation outcomes and association with serum sodium concentrations between groups. Mortality within 90 days on the liver waitlist decreased (hazard ratio [HR] 0.738, P < .001) and transplantation probability increased significantly (HR 1.217, P < .001) in the MELD-Na period. Although mild, moderate, and severe hyponatremia (130-134, 125-129, and <125 mmol/L) were independent risk factors for waitlist mortality in the MELD period (HR 1.354, 1.762, and 2.656; P < .001, P < .001, and P < .001, respectively) compared with the reference standard (135-145 mmol/L), these adverse outcomes were decreased in the MELD-Na period (HR 1.092, 1.271 and 1.374; P = .27, P = .018, and P = .037, respectively). The adjusted survival benefit of transplant recipients vs patients placed on the waitlist in the same score categories was definitive for patients with MELD-Na scores of 21-23 in the MELD-Na era (HR 0.336, P < .001) compared with MELD scores of 15-17 in the MELD era (HR 0.365, P < .001). Liver allocation based on MELD-Na score successfully improved waitlist outcomes and provided significant benefit to hyponatremic patients. Given the discrepancy in transplantation survival benefit, the current rules for liver allocation might require revision.

27 May 2021 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
SNShunji Nagai
Shunji Nagai
YSYukiko Suzuki
Yukiko Suzuki
TKToshihiro Kitajima
Toshihiro Kitajima
TITommy Ivanics
Tommy Ivanics
SSShingo Shimada
Shingo Shimada
MAMarwan Abouljoud
Marwan Abouljoud

25 January 2021 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
TKToshihiro Kitajima
Toshihiro Kitajima
DMDilip Moonka
Dilip Moonka
SYSirisha Yeddula
Sirisha Yeddula
KCKelly Collins
Kelly Collins
MRMichael Rizzari
Michael Rizzari
SNShunji Nagai
Shunji Nagai

5 April 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
TSTayseer M. Shamaa
Tayseer M. Shamaa
OSOmar Shamaa
Omar Shamaa
CCCatherine Crombez
Catherine Crombez
JKJonathan M. Konel
Jonathan M. Konel
TKToshihiro Kitajima
Toshihiro Kitajima
MRMichael Rizzari
Michael Rizzari
Combined liver and lung transplantation (CLLT) is indicated in patients with both end-stage liver and lung disease. Ex-situ normothermic machine perfusion (NMP) has been previously used for extended normothermic lung preservation in CLLT. We aim to describe our single-center experience using ex-situ NMP for extended normothermic liver preservation in CLLT. Four CLLTs were performed from 2019 to 2020 with the lung transplanted first for all patients. Median ex-situ pump time for the liver was 413 min (IQR 400-424). Over a median follow-up of 15 months (IQR 14-19), all patients were alive and doing well. Normothermic extended liver preservation is a safe method to allow prolonged cold ischemia using normothermic perfusion of the liver during CLLT.

25 November 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SSShingo Shimada
Shingo Shimada
TSTayseer Shamaa
Tayseer Shamaa
TITommy Ivanics
Tommy Ivanics
TKToshihiro Kitajima
Toshihiro Kitajima
MAMohamed Adhnan
Mohamed Adhnan
SNShunji Nagai
Shunji Nagai

14 August 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
TITommy Ivanics
Tommy Ivanics
MRMichael Rizzari
Michael Rizzari
DMDilip Moonka
Dilip Moonka
AAAbbas Al-Kurd
Abbas Al-Kurd
KDKhortnal Delvecchio
Khortnal Delvecchio
SNShunji Nagai
Shunji Nagai
The success of direct‐acting antiviral (DAA) therapy has led to near‐universal cure for patients chronically infected with hepatitis C virus (HCV) and improved post‐liver transplant(LT) outcomes. We investigated the trends and outcomes of re‐transplantation in HCV and non‐HCV patients before and after the introduction of DAA. Adult patients who underwent re‐LT were identified in the OPTN/UNOS database. Multi‐organ transplants and patients with more than two total LTs were excluded. Two eras were defined, pre‐DAA(2009‐2012), and post‐DAA(2014‐2017). A total of 2,112 re‐LT patients were eligible(HCV: n=499 pre‐DAA and n=322 post‐DAA; non‐HCV: n=547 pre‐DAA and n=744 post‐DAA). HCV patients had both improved graft and patient survival after re‐LT in the post‐DAA era. One‐year graft survival was 69.8% pre‐DAA and 83.8% post‐DAA(p<0.001). One‐year patient survival was 73.1% pre‐DAA and 86.2% post‐DAA(p<0.001).Graft and patient survival was similar between eras for non‐HCV patients. When adjusted, the post‐DAA era represented an independent positive predictive factor for graft and patient survival(HR:0.67;p=0.005,and HR:0.65;p=0.004) only in HCV patients. The positive post‐DAA era effect was observed only in HCV patients with first graft loss due to disease recurrence(HR:0.31;p=0.002, HR 0.32;p=0.003, respectively). Among HCV patients, receiving a re‐LT in the post‐DAA era was associated with improved patient and graft survival.